Carroll T, Findling J W
Endocrinology Center and Clinics, Medical College of Wisconsin, Menomonee Falls, WI, USA.
Drugs Today (Barc). 2012 Aug;48(8):509-18. doi: 10.1358/dot.2012.48.8.1841299.
Patients with endogenous hypercortisolism, Cushing's syndrome, have significant morbidity and increased mortality when inadequately treated. When surgical therapy has been unsuccessful other treatment modalities are necessary. Previously available therapies have limited effectiveness or significant toxicity. Mifepristone, a glucocorticoid receptor antagonist, provides a novel approach to the treatment of hypercortisolism. It is rapidly absorbed, highly protein bound and has a long plasma half-life. Since it also serves as a progesterone receptor antagonist, mifepristone has been used in several other medical conditions. A recently published prospective trial of mifepristone therapy for Cushing's syndrome resulted in its recent approval by the U.S. Food and Drug Administration for use in Cushing's syndrome.
患有内源性皮质醇增多症（库欣综合征）的患者若治疗不当，会有较高的发病率和死亡率。当手术治疗失败时，就需要采取其他治疗方式。以前可用的治疗方法效果有限或毒性较大。米非司酮是一种糖皮质激素受体拮抗剂，为治疗皮质醇增多症提供了一种新方法。它吸收迅速，高度与蛋白质结合，血浆半衰期长。由于它还可作为孕激素受体拮抗剂，米非司酮已被用于其他多种医疗状况。最近发表的一项关于米非司酮治疗库欣综合征的前瞻性试验，导致其最近获得美国食品药品监督管理局批准用于库欣综合征。
